Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02151630
Recruitment Status : Unknown
Verified May 2014 by Fatima Assaf, Isfahan University of Medical Sciences.
Recruitment status was:  Recruiting
First Posted : May 30, 2014
Last Update Posted : May 30, 2014
Sponsor:
Information provided by (Responsible Party):
Fatima Assaf, Isfahan University of Medical Sciences

Brief Summary:
Plantar warts can be bothersome and painful requiring treatment. The investigators will compare the efficacy of pyruvic acid and salicylic acid in treating multiple plantar warts. Patients with multiple plantar warts will be randomized to receive either pyruvic acid 70% or compound salicylic acid solution (salicylic acid 16.7%, lactic acid 16.7%, and collodion 100%) applying topically twice a day for 4 weeks. Patients will be visited every 2 weeks for one month after starting treatment and then every one month for up to 3 months. The number and size of warts will be evaluated.

Condition or disease Intervention/treatment Phase
Plantar Wart Drug: Pyruvic acid Drug: Salicylic Acid Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of 70% Pyruvic Acid Solution and Duofilm Solution in Treatment of Plantar Wart
Study Start Date : May 2014
Estimated Primary Completion Date : September 2014
Estimated Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Warts

Arm Intervention/treatment
Active Comparator: Pyruvic acid
Patients will receive pyruvic acid solution 70% prepared by solving of pyruvic acid in water/ethanol solution. Patients will be advised to apply the solution twice daily for a period of four weeks. Application of petrolatum to the surrounding normal skin protects against the corrosive effect of the concentrated acid.
Drug: Pyruvic acid
Active Comparator: Salicylic acid
Patients will receive a combination of salicylic acid 16.7%, lactic acid 16.7%, and collodion 100%. Patients will be advised to apply the solution twice daily for a period of four weeks. Application of petrolatum to the surrounding normal skin protects against the corrosive effect of the concentrated acid.
Drug: Salicylic Acid



Primary Outcome Measures :
  1. Wart number [ Time Frame: From before to 3 months after ]
    Patients will be visited every two weeks for one month and then every month for up to 3 months by a dermatologist. On each visit, warts will be inspected to determine the number of warts. Any wart totally non-detectable by inspection and touch will be considered as healed.

  2. Wart size [ Time Frame: From before to 3 months after ]
    Patients will be visited every two weeks for one month and then every month for up to 3 months by a dermatologist. On each visit, warts will be inspected to determine the size of warts. The size of the warts will be calculated as the mean size of all the warts.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • aged 12 years and above
  • multiple warts (at least 2)

Exclusion Criteria:

  • mosaic warts
  • already under any treatment for warts
  • pregnant or lactating women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02151630


Contacts
Layout table for location contacts
Contact: Fatima Assaf, M.D. 0098 913 0965384 dr.assafsaid@gmail.com

Locations
Layout table for location information
Iran, Islamic Republic of
Skin Diseases and Leishmaniasis Research Center Recruiting
Isfahan, Iran, Islamic Republic of
Contact: Fatima Assaf, M.D.    0098 913 0965384    dr.assafsaid@gmail.com   
Principal Investigator: Fatima Assaf, M.D.         
Sponsors and Collaborators
Isfahan University of Medical Sciences
Investigators
Layout table for investigator information
Principal Investigator: Fatima Assaf, M.D. Isfahan University of Medical Sciences

Publications:
Layout table for additonal information
Responsible Party: Fatima Assaf, Dr., Isfahan University of Medical Sciences
ClinicalTrials.gov Identifier: NCT02151630     History of Changes
Other Study ID Numbers: 393219
First Posted: May 30, 2014    Key Record Dates
Last Update Posted: May 30, 2014
Last Verified: May 2014
Keywords provided by Fatima Assaf, Isfahan University of Medical Sciences:
wart
verruca vulgaris
topical therapy
pyruvic acid
salicylic acid
Additional relevant MeSH terms:
Layout table for MeSH terms
Warts
Foot Diseases
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Tumor Virus Infections
Skin Diseases, Infectious
Skin Diseases
Musculoskeletal Diseases
Salicylic Acid
Salicylates
Anti-Infective Agents
Antifungal Agents
Keratolytic Agents
Dermatologic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action